These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12422001)

  • 21. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial.
    Haibel H; Brandt HC; Song IH; Brandt A; Listing J; Rudwaleit M; Sieper J
    Ann Rheum Dis; 2007 Mar; 66(3):419-21. PubMed ID: 16901959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
    de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2007 Sep; 66(9):1252-4. PubMed ID: 17472991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up.
    Gossec L; Le Henanff A; Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Alexandre C; Dougados M
    Rheumatology (Oxford); 2006 Jul; 45(7):859-62. PubMed ID: 16436489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates vs infliximab in ankylosing spondylitis treatment.
    Viapiana O; Gatti D; Idolazzi L; Fracassi E; Adami S; Troplini S; Povino MR; Rossini M
    Rheumatology (Oxford); 2014 Jan; 53(1):90-4. PubMed ID: 24067888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis.
    Pérez-Guijo VC; Cravo AR; Castro Mdel C; Font P; Muñoz-Gomariz E; Collantes-Estevez E
    Joint Bone Spine; 2007 May; 74(3):254-8. PubMed ID: 17387031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab treatment in ankylosing spondylitis: an observational study.
    Nikas SN; Alamanos Y; Voulgari PV; Pliakou XI; Papadopoulos CG; Drosos AA
    Ann Rheum Dis; 2005 Jun; 64(6):940-2. PubMed ID: 15564309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab in two patients with juvenile ankylosing spondylitis.
    Schmeling H; Horneff G
    Rheumatol Int; 2004 May; 24(3):173-6. PubMed ID: 14648110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade.
    Syngle A; Vohra K; Sharma A; Kaur L
    Clin Rheumatol; 2010 Jul; 29(7):763-70. PubMed ID: 20204669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1.
    Sieper J; Lenaerts J; Wollenhaupt J; Rudwaleit M; Mazurov VI; Myasoutova L; Park S; Song Y; Yao R; Chitkara D; Vastesaeger N;
    Ann Rheum Dis; 2014 Jan; 73(1):101-7. PubMed ID: 23696633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy.
    Genre F; López-Mejías R; Miranda-Filloy JA; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda J; González-Juanatey C; Llorca J; González-Gay MÁ
    Clin Exp Rheumatol; 2013; 31(6):913-8. PubMed ID: 23981480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
    Sieper J; Rudwaleit M; Lenaerts J; Wollenhaupt J; Myasoutova L; Park SH; Song YW; Yao R; Huyck S; Govoni M; Chitkara D; Vastesaeger N
    Rheumatology (Oxford); 2016 Nov; 55(11):1946-1953. PubMed ID: 27411482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Flexibilization of infliximab dose interval in the treatment of ankylosing spondylitis].
    Vinagre F; Santos MJ; Silva JC
    Acta Reumatol Port; 2007; 32(3):271-3. PubMed ID: 17940497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
    Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
    J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab.
    Heldmann F; Brandt J; van der Horst-Bruinsma IE; Landewe R; Sieper J; Burmester GR; van den Bosch F; de Vlam K; Geusens P; Gaston H; Schewe S; Appelboom T; Emery P; Dougados M; Leirisalo-Repo M; Breban M; Listing J; Braun J
    Clin Exp Rheumatol; 2011; 29(4):672-80. PubMed ID: 21906431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O; Bashkin A; Mandelboim M; Litinsky I; Comaheshter D; Levartovsky D; Mendelson E; Wigler I; Caspi D; Paran D
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.
    Barkham N; Keen HI; Coates LC; O'Connor P; Hensor E; Fraser AD; Cawkwell LS; Bennett A; McGonagle D; Emery P
    Arthritis Rheum; 2009 Apr; 60(4):946-54. PubMed ID: 19333933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
    Poddubnyy D; Hermann KG; Callhoff J; Listing J; Sieper J
    Ann Rheum Dis; 2014 May; 73(5):817-23. PubMed ID: 24389297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis.
    Chu Miow Lin D; Mulleman D; Azzopardi N; Griffoul-Espitalier I; Valat JP; Paintaud G; Goupille P
    Scand J Rheumatol; 2010; 39(1):97-8. PubMed ID: 20132079
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.